Damle NK[au] - Search Results

Year	Number of Results
1979	3
1981	2
1982	2
1983	4
1984	4
1985	4
1986	3
1987	3
1988	2
1989	4
1990	3
1991	5
1992	6
1993	8
1994	1
1995	1
2002	1
2003	2
2004	4
2005	2
2006	4
2007	3
2008	3
2010	1
2011	1
2021	1
2022	0

1

Tumour-targeted chemotherapy with immunoconjugates of calicheamicin.

Damle NK. Damle NK. Expert Opin Biol Ther. 2004 Sep;4(9):1445-52. doi: 10.1517/14712598.4.9.1445. Expert Opin Biol Ther. 2004. PMID: 15335312 Review.

2

Biopharmaceutical drug discovery using novel protein scaffolds.

Gill DS, Damle NK. Gill DS, et al. Among authors: damle nk. Curr Opin Biotechnol. 2006 Dec;17(6):653-8. doi: 10.1016/j.copbio.2006.10.003. Epub 2006 Oct 19. Curr Opin Biotechnol. 2006. PMID: 17055245 Review.

3

Antibody-targeted chemotherapy with immunoconjugates of calicheamicin.

Damle NK, Frost P. Damle NK, et al. Curr Opin Pharmacol. 2003 Aug;3(4):386-90. doi: 10.1016/s1471-4892(03)00083-3. Curr Opin Pharmacol. 2003. PMID: 12901947 Review.

4

Antigen-specific suppressor T lymphocytes in man.

Damle NK, Engleman EG. Damle NK, et al. Clin Immunol Immunopathol. 1989 Nov;53(2 Pt 2):S17-24. doi: 10.1016/0090-1229(89)90066-4. Clin Immunol Immunopathol. 1989. PMID: 2551552 Review.

5

Interleukin 2-activated killer lymphocytes in man.

Damle NK, Bradley EC. Damle NK, et al. Year Immunol. 1988;3:138-43. Year Immunol. 1988. PMID: 3327308 Review. No abstract available.

6

Antibody-drug conjugates ace the tolerability test.

Damle NK. Damle NK. Nat Biotechnol. 2008 Aug;26(8):884-5. doi: 10.1038/nbt0808-884. Nat Biotechnol. 2008. PMID: 18688241 No abstract available.

7

Immunoregulatory T lymphocytes in man. Cell surface molecules involved in their function.

Damle NK, Engleman EG. Damle NK, et al. Year Immunol. 1985:39-50. Year Immunol. 1985. PMID: 2953144 Review. No abstract available.

8

ASN004, A 5T4-targeting scFv-Fc Antibody-Drug Conjugate with High Drug-to-Antibody Ratio, Induces Complete and Durable Tumor Regressions in Preclinical Models.

Smith RA, Zammit DJ, Damle NK, Usansky H, Reddy SP, Lin JH, Mistry M, Rao NS, Denis LJ, Gupta S. Smith RA, et al. Among authors: damle nk. Mol Cancer Ther. 2021 Aug;20(8):1327-1337. doi: 10.1158/1535-7163.MCT-20-0565. Epub 2021 May 27. Mol Cancer Ther. 2021. PMID: 34045226

9

Suppressor T lymphocytes in man. Facts and views.

Damle NK. Damle NK. Year Immunol. 1986;2:60-7. Year Immunol. 1986. PMID: 2953147 Review. No abstract available.

10

The oncofetal protein, 5T4, is a suitable target for antibody-guided anti-cancer chemotherapy with calicheamicin.

Boghaert ER, Sridharan L, Khandke KM, Armellino D, Ryan MG, Myers K, Harrop R, Kunz A, Hamann PR, Marquette K, Dougher M, DiJoseph JF, Damle NK. Boghaert ER, et al. Among authors: damle nk. Int J Oncol. 2008 Jan;32(1):221-34. doi: 10.3892/ijo.32.1.221. Int J Oncol. 2008. PMID: 18097562

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results